Last updated: February 16, 2026
What is NDC 64980-0442?
NDC 64980-0442 refers to Ibrutinib (Imbruvica), a targeted kinase inhibitor approved for multiple hematological cancers, including mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), Waldenström’s macroglobulinemia (WM), and marginal zone lymphoma (MZL). It is marketed by AbbVie and Janssen.
Market Size and Adoption Trends
Current Market Scope
- Global sales for Ibrutinib reached approximately $8.8 billion in 2022, with North America accounting for about 75%, reflecting high adoption rates.
- The U.S. accounts for nearly 70% of sales, driven by FDA approvals and supportive reimbursement policies.
- The drug’s use expanded from CLL in 2014 to include MCL (2014), WM (2017), and MZL (2022), broadening its market.
Market Drivers
- Rising incidence of B-cell malignancies; US cancer registry estimated 80,000 new CLL cases annually.
- Increasing adoption as a first-line therapy in eligible patients.
- Expanding label indications and combination therapies.
- Growing prevalence of drug-resistant disease forms.
Competitive Landscape
- Main competitors include acalabrutinib (Calquence), zanubrutinib (Brukinsa), and newer non-BTK inhibitors.
- Acalabrutinib started gaining market share from 2018; the competitive edge relies on safety profile and price.
Pricing Dynamics and Reimbursement Environment
List Price
- The average wholesale price (AWP) for a 140 mg capsule is approximately $887.
- Monthly cost varies but averages $17,740 (based on a typical dosing of 420 mg/day).
Reimbursement and Discounting
- Net price levels are lower due to discounts, rebates, and patient assistance programs.
- The average commercial payor reimbursement rate is estimated at 30-40% below list price.
- Medicare Part D reimbursements are subject to negotiated prices and formulary placements.
Pricing Trends
- Since 2017, per-unit price increases have been limited; price stabilization occurs due to competitive pressures.
- Prices for similar targeted agents have increased cumulatively 2-3% annually since 2010, adjusted for inflation and market conditions.
Projection Assumptions (2023-2028)
| Year |
Estimated Market Share |
Estimated Adoption Rate |
Price per Unit |
Expected Sales (USD millions) |
| 2023 |
60% (of BTK inhibitors) |
65% of target patient population |
$887 per capsule |
$7,000 - $8,200 |
| 2024 |
65% |
70% |
$890 |
$8,100 - $9,200 |
| 2025 |
70% |
75% |
$890 |
$9,300 - $10,500 |
| 2026 |
70% |
77% |
$890 |
$9,900 - $11,400 |
| 2027 |
75% |
80% |
$890 |
$10,500 - $12,200 |
| 2028 |
75% |
83% |
$890 |
$11,200 - $13,000 |
Key Drivers in projections include increased prevalence of target indications, improved line-of-therapy positioning, and expanded coverage. Market share is set to stabilize around 75%, with prices stable but offset by potential biosimilar/competitor entries after patent expiry (~2029).
Patent and Regulatory Outlook
- The primary patent for Ibrutinib expires around 2029; biosimilar competition is expected thereafter.
- No recent FDA label changes suggest stable regulatory status through 2028.
- Future pricing depends on patent litigation outcomes, biosimilar development, and payer policies.
Potential Impact of Biosimilars and Competition
- Biosimilar candidates could enter from 2028 onward, potentially reducing prices by 30-50% in subsequent years.
- Price erosion might accelerate if competitive products demonstrate comparable efficacy and safety profiles.
Summary of Key Factors and Risks
| Factor |
Impact |
Risk Level |
| Patent expiry |
Price decline after 2029 |
High |
| Competition |
Price pressure from alternatives |
Medium-High |
| Market penetration |
Increased adoption stabilizes revenue |
Medium |
| Regulatory approvals |
Broader indications |
Low-Medium |
| Reimbursement policies |
Can either stabilize or erode margins |
Medium |
Key Takeaways
- The current US market for NDC 64980-0442 (Ibrutinib) is approximately $8-9 billion annually.
- Prices hover around $890 per capsule, with slight growth anticipated through 2028.
- Market share is expected to plateau at about 75% amidst competition.
- Patent expiration in 2029 raises prospects for biosimilar pressure, likely leading to significant price reductions thereafter.
- The primary growth driver remains the expansion of indications and increasing adoption in earlier lines of therapy.
FAQs
1. When do biosimilar competitors for Ibrutinib likely enter the market?
Entry is projected around 2029, post-patent expiry, with potential initial launches delayed by regulatory and manufacturing processes.
2. How will new indications affect the market?
Approval for additional indications could expand the addressable patient population, driving sales growth until biosimilar entry.
3. What factors could influence the drug’s price stability?
Reimbursement policies, formulary negotiations, and clinical guideline updates could either stabilize or pressure prices.
4. How does the competition from acalabrutinib and zanubrutinib impact pricing?
These competitors offer similar efficacy with differing safety profiles. Market share shifts toward them can reduce the dominant drug’s price and revenue.
5. Are there emerging therapies that threaten Ibrutinib’s market share?
Yes, non-BTK targeted therapies and combination regimens under development could displace Ibrutinib in certain indications.
Citations
[1] IQVIA, "Market Trends for Oncology Drugs," 2022.
[2] FDA, "Ibrutinib (Imbruvica) Label Approvals," 2022.
[3] EvaluatePharma, "Oncology Market Forecast," 2023.
[4] CMS, "Medicare Drug Reimbursements," 2023.
[5] Recent patent filings and patent expiry analysis, 2023.
